Experiences with the use of oxaliplatin in esophageal carcinoma

Albertsson, Maria; Kadar, Lianna; Bergenfeldt, Magnus

doi:10.1080/02841860500372319

Cited by 1 publication

(1 citation statement)

References 6 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is likely that patients with metastatic disease confined only to the cervical or celiac lymph node can survive longer than expected, and achieve more benefit from adjuvant chemotherapy. A couple of new cytotoxic drugs are available on the market, and they show a higher response rate than the standard 5‐FU and DDP in advanced esophageal cancer 22–25 . A prospective phase III clinical trial comparing 5‐FU plus LV and oxaliplatin with 5‐FU and DDP plus LV for adjuvant chemotherapy of patients with stages IIb, III, IV esophageal cancer is ongoing in our cancer center, and we are looking forward to seeing whether the new drugs can exert a highly potent anticancer action in the adjuvant setting of esophageal cancer.…”

Section: Discussionmentioning

confidence: 99%

Adjuvant chemotherapy of cisplatin, 5-fluorouracil and leucovorin for complete resectable esophageal cancer: a case-matched cohort study in east China

et al. 2008

View full text Add to dashboard Cite

It is still controversial whether adjuvant chemotherapy of cisplatin, 5-fluorouracil and leucovorin can increase the overall survival of esophageal cancer patients, and which subgroup of patients get most benefits from it. Between 1998 and 2004, 66 esophageal cancer patients with adjuvant chemotherapy and 160 well-matched patients without chemotherapy were included in this study. Nine markers were measured in the protein level to analyze prognostic significance. In the whole group, adjuvant chemotherapy did not improve the survival of esophageal cancer patients. There was also no significant difference for survival in stage I (P=0.59 and P=0.59), stage II (P=0.28 and P=0.28) and stage III patients (P=0.144 and P=0.06) between the observation and the chemotherapy group. Chemotherapy was most effective for the patients who had metastases in cervical and/or celiac lymph nodes (IV subgroup). One and 3-year disease-free survival and overall survival were significantly better than for those who did not receive the chemotherapy(P=0.038, and 0.016, respectively). Bcl-2 expression was a bad prognostic factor, and was more predictive in the adjuvant chemotherapy group than in the no-chemotherapy group. Adjuvant chemotherapy significantly improved the treatment result of stage IV patients compared with the observation group. Bcl-2 could be used to analyze prognosis and guide the adjuvant treatment.

show abstract

Section: Discussionmentioning

confidence: 99%